Shares of Fibrocell Science Inc (NASDAQ:FCSC) saw unusually-strong trading volume on Wednesday . Approximately 8,612,477 shares traded hands during trading, an increase of 2,921% from the previous session’s volume of 285,053 shares.The stock last traded at $2.35 and had previously closed at $1.97.

Several equities research analysts recently weighed in on FCSC shares. Zacks Investment Research downgraded shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research report on Wednesday, February 13th. ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $11.33.

The stock has a market cap of $17.95 million, a price-to-earnings ratio of -0.28 and a beta of 1.60.

A hedge fund recently raised its stake in Fibrocell Science stock. Renaissance Technologies LLC lifted its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 126.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 367,941 shares of the company’s stock after acquiring an additional 205,660 shares during the period. Renaissance Technologies LLC owned approximately 3.95% of Fibrocell Science worth $868,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 27.75% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Fibrocell Science Company Profile (NASDAQ:FCSC)

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

See Also: Yield Curve

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.